273 related articles for article (PubMed ID: 17048248)
21. Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel.
Furst DE; Halbert RJ; Bingham CO; Fukudome S; Anderson L; Bonafede P; Bray V; Cohen SB; Sherrer YR; St Clair EW; Tesser JR; Weinblatt M; Dubois RW
Rheumatology (Oxford); 2008 Feb; 47(2):194-9. PubMed ID: 18178593
[TBL] [Abstract][Full Text] [Related]
22. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
24. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.
Russo P; O'Brien MF
Urol Clin North Am; 2008 Nov; 35(4):679-86; viii. PubMed ID: 18992621
[TBL] [Abstract][Full Text] [Related]
25. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
26. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
Tan TH; Pranavan G; Haxhimolla HZ; Yip D
Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
[TBL] [Abstract][Full Text] [Related]
27. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
28. Metastatic renal cell carcinoma: many treatment options, one patient.
Rini BI
J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934
[TBL] [Abstract][Full Text] [Related]
29. Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
Kirchner H; Strumberg D; Bahl A; Overkamp F
Expert Rev Anticancer Ther; 2010 Apr; 10(4):585-96. PubMed ID: 20397923
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy of renal cell cancer.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
32. Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).
Gore ME; Bellmunt J; Eisen T; Escudier B; Mickisch G; Patard J; Porta C; Ravaud A; Schmidinger M; Schöffski P; Sternberg CN; Szczylik C; Lewis S; Kirpekar S
Eur J Cancer; 2014 Dec; 50(18):3153-60. PubMed ID: 25442842
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
34. Patterns of care in adults with renal cell carcinoma: findings in a population based sample.
Yabroff KR; Harlan L; Stevens J; Martin A
J Urol; 2009 Jun; 181(6):2462-8; discussion 2469. PubMed ID: 19371892
[TBL] [Abstract][Full Text] [Related]
35. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
36. Current clinical trials in renal cell carcinoma.
Sokoloff MH; Daneshmand S; Ryan CW
Urol Oncol; 2005; 23(4):289-92. PubMed ID: 16018946
[TBL] [Abstract][Full Text] [Related]
37. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
38. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Amin C; Wallen E; Pruthi RS; Calvo BF; Godley PA; Rathmell WK
Urology; 2008 Oct; 72(4):864-8. PubMed ID: 18684493
[TBL] [Abstract][Full Text] [Related]
39. Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.
Powles T; Albers P
Clin Genitourin Cancer; 2012 Dec; 10(4):213-8. PubMed ID: 22939100
[TBL] [Abstract][Full Text] [Related]
40. [Prise en charge of metastatic renal carcinoma].
Méjean A; Lebret T
Prog Urol; 2008 Nov; 18 Suppl 7():S298-308. PubMed ID: 19070807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
